| pubmed-article:16324917 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16324917 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:16324917 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:16324917 | lifeskim:mentions | umls-concept:C0011777 | lld:lifeskim |
| pubmed-article:16324917 | lifeskim:mentions | umls-concept:C0205409 | lld:lifeskim |
| pubmed-article:16324917 | lifeskim:mentions | umls-concept:C1155436 | lld:lifeskim |
| pubmed-article:16324917 | lifeskim:mentions | umls-concept:C1256369 | lld:lifeskim |
| pubmed-article:16324917 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16324917 | pubmed:dateCreated | 2005-12-5 | lld:pubmed |
| pubmed-article:16324917 | pubmed:abstractText | Dexamethasone inhibits insulin secretion from isolated islets. In the present experiments, possible underlying biochemical mechanisms responsible for defective secretion were explored. Dexamethasone (1 micromol/L) had no immediate deleterious effect on 15 mmol/L glucose-induced insulin release from perifused rat islets. However, a 3-hour preincubation period with 1 micromol/L dexamethasone resulted in parallel reductions in both the first (64%) and second phases (74%) of 15 mmol/L glucose-induced insulin secretion monitored during a dynamic perifusion. When measured after the perifusion, there were no differences in insulin content or in the capacity of control or dexamethasone-treated islets to use glucose. Dexamethasone (1 micromol/L) preexposure also reduced phorbol ester- and potassium-induced secretion. In additional experiments, islets were labeled for 3 hours with 3H-inositol in the presence or absence of 1 micromol/L dexamethasone. The steroid did not affect total 3H-inositol incorporation during the labeling period. However, the capacity of 15 mmol/L glucose, 30 mmol/L KCl, and 100 micromol/L carbachol to activate phospholipase C (PLC), monitored by the accumulation of labeled inositol phosphates, was significantly reduced in dexamethasone-pretreated islets. Inclusion of the nuclear glucocorticoid receptor antagonist RU486 (mifepristone, 10 micromol/L) abolished the adverse effects of dexamethasone on both glucose-induced inositol phosphate accumulation and insulin secretion. Quantitative Western blot analyses revealed that the islet contents of PLCdelta1, PLCbeta1, beta2, beta3, and protein kinase C alpha were unaffected by dexamethasone pretreatment. These findings demonstrate that dexamethasone pretreatment impairs insulin secretion via a genomic action and that impaired activation of the PLC/protein kinase C signaling system is involved in the evolution of its inhibitory effect on secretion. | lld:pubmed |
| pubmed-article:16324917 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16324917 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16324917 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16324917 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:16324917 | pubmed:issn | 0026-0495 | lld:pubmed |
| pubmed-article:16324917 | pubmed:author | pubmed-author:YamazakiHanae... | lld:pubmed |
| pubmed-article:16324917 | pubmed:author | pubmed-author:ZawalichWalte... | lld:pubmed |
| pubmed-article:16324917 | pubmed:author | pubmed-author:ZawalichKathl... | lld:pubmed |
| pubmed-article:16324917 | pubmed:author | pubmed-author:TeszGregory... | lld:pubmed |
| pubmed-article:16324917 | pubmed:author | pubmed-author:PhilbrickWill... | lld:pubmed |
| pubmed-article:16324917 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16324917 | pubmed:volume | 55 | lld:pubmed |
| pubmed-article:16324917 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16324917 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16324917 | pubmed:pagination | 35-42 | lld:pubmed |
| pubmed-article:16324917 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:meshHeading | pubmed-meshheading:16324917... | lld:pubmed |
| pubmed-article:16324917 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16324917 | pubmed:articleTitle | Dexamethasone suppresses phospholipase C activation and insulin secretion from isolated rat islets. | lld:pubmed |
| pubmed-article:16324917 | pubmed:affiliation | Yale University School of Nursing, New Haven, CT 06536-0740, USA. walter.zawalich@yale.edu | lld:pubmed |
| pubmed-article:16324917 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16324917 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:16324917 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16324917 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16324917 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16324917 | lld:pubmed |
